Brokerages Anticipate Imv Inc (NYSE:IMV) Will Announce Earnings of -$0.09 Per Share

Share on StockTwits

Wall Street brokerages expect Imv Inc (NYSE:IMV) to report earnings of ($0.09) per share for the current quarter, according to Zacks. Two analysts have made estimates for IMV’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.08). IMV reported earnings per share of ($0.11) in the same quarter last year, which would suggest a positive year over year growth rate of 18.2%. The firm is expected to issue its next quarterly earnings results on Friday, November 1st.

On average, analysts expect that IMV will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.32). For the next financial year, analysts expect that the company will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.43) to ($0.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow IMV.

IMV (NYSE:IMV) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.07 million.

IMV has been the topic of a number of research reports. Echelon Wealth Partners reissued a “buy” rating on shares of IMV in a research report on Tuesday, June 4th. Zacks Investment Research raised shares of IMV from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Wednesday, August 14th. B. Riley started coverage on shares of IMV in a research report on Wednesday, May 29th. They issued a “buy” rating and a $11.00 price objective on the stock. Raymond James set a $10.00 price objective on shares of IMV and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.50 price objective on shares of IMV in a research report on Wednesday, June 12th. Five equities research analysts have rated the stock with a buy rating, IMV currently has an average rating of “Buy” and an average target price of $8.81.

A number of hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in IMV by 3.6% in the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after purchasing an additional 3,453 shares in the last quarter. Hartford Financial Management Inc. boosted its stake in IMV by 20.1% in the 1st quarter. Hartford Financial Management Inc. now owns 32,250 shares of the company’s stock worth $129,000 after purchasing an additional 5,400 shares in the last quarter. Bank of Montreal Can boosted its stake in IMV by 18.5% in the 1st quarter. Bank of Montreal Can now owns 75,661 shares of the company’s stock worth $304,000 after purchasing an additional 11,807 shares in the last quarter. Citadel Advisors LLC acquired a new stake in IMV in the 2nd quarter worth approximately $37,000. Finally, Ironwood Investment Management LLC acquired a new stake in IMV in the 1st quarter worth approximately $135,000.

NYSE IMV traded up $0.04 during trading on Tuesday, reaching $3.29. 2,810 shares of the company’s stock traded hands, compared to its average volume of 22,619. The company’s 50 day simple moving average is $2.82 and its two-hundred day simple moving average is $3.42. IMV has a 12-month low of $2.25 and a 12-month high of $7.07.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

See Also: What does a neutral rating on stocks mean?

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.